STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B-Cell Lymphoma

Jennifer Hardee,*1 Zhengqing Ouyang,*1,2,3 Yuping Zhang,*4 Anshul Kundaje,*1 Philippe Lacroute,* and Michael Snyder*,†

*Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, †Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520, and ‡Department of Computer Science, Stanford University School of Engineering, Stanford, California 94305

ABSTRACT The signal transducer and activator of transcription 3 (STAT3) is a transcription factor that, when dysregulated, becomes a powerful oncogene found in many human cancers, including diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin’s lymphoma and has two major subtypes: germinal center B-cell—like and activated B-cell—like. Compared with the germinal center B-cell—like form, activated B-cell—like lymphomas respond much more poorly to current therapies and often exhibit overexpression or overactivation of STAT3. To investigate how STAT3 might contribute to this aggressive phenotype, we have integrated genome-wide studies of STAT3 DNA binding using chromatin immunoprecipitation-sequencing with whole-transcriptome profiling using RNA-sequencing. STAT3 binding sites are present near almost a third of all genes that differ in expression between the two subtypes, and examination of the affected genes identified previously undetected and clinically significant pathways downstream of STAT3 that drive oncogenesis. Novel treatments aimed at these pathways may increase the survivability of activated B-cell—like diffuse large B-cell lymphoma.

The transcription factor signal transducer and activator of transcription 3 (STAT3) is a key signal transducer that regulates gene expres-

sion in response to interleukins and cytokines, as well as a wide variety of other extracellular signals (Zhong et al. 1994; Baker et al. 2007; Minegishi 2009). The binding of one of these messengers to its receptor launches a tyrosine phosphorylation cascade that results in the cytosolic activation and dimerization of STAT3, which is then imported to the nucleus, where it binds its target sequences. STAT3 mediates the expression of a large number of genes and plays a key role in many cellular processes, especially those related to cell growth and apoptosis (Baker et al. 2007).

As the result of these proliferative and antiapoptotic effects, STAT3 is also a powerful oncogene (Alvarez and Frank 2004). Constitutively active STAT3, caused by upstream dysregulation, is found in a large number of human cancers and is generally associated with a poorer prognosis (Benekli et al. 2003; Turkson 2004; Hodge et al. 2005). In particular, overactive STAT3 is frequently found in diffuse large B-cell lymphoma (DLBCL) and is associated with poorer outcomes (Ding et al. 2008; Wu et al. 2011). DLBCL is the most common form of lymphoma and comprises at least two subtypes: germinal center B-cell—like (GCB) and activated B-cell—like (ABC) (Alizadeh et al. 2000; Rosenwald et al. 2002; Wright et al. 2003; American Cancer Society 2012). These two subtypes have significant differences in three-year survival, which is nearly 85% for GCB but only 65–70% for patients with ABC (Fu et al. 2008; Lenz et al. 2008). High levels of STAT3 generally are found only in the activated B-cell—like subtype.
In the present study, we sought to further understand the difference in STAT3 function between these two subtypes through mapping its binding regions (BRs) and analyzing gene expression in GCB and ABC patient tumor–derived cell lines. We performed ChIP-Seq (chromatin immunoprecipitation followed by DNA sequencing) experiments to map STAT3 binding sites and RNA-Seq to analyze the global gene expression patterns. We then synthesized these data to determine which genetic loci show both differential STAT3 binding and differential mRNA expression. We found that STAT3 likely up-regulates a number of oncogenic pathways to promote aggressive tumor growth and migration.

MATERIALS AND METHODS

Cell lines were grown at 37° and 5% CO2. SU-DHL2, SU-DHL4, SU-DHL6, SU-DHL10, OCI-Ly7, and U-2932 were grown in RPMI 1640 media supplemented with 15% FBS and antibiotics. OCI-Ly3 and OCI-Ly10 were grown in IMDM media supplemented with 15% fetal bovine serum, antibiotics, and 55 μM beta-mercaptoethanol. Western blots were performed on whole-cell lysate, with equal protein loading in each lane, with the use of anti-STAT3 rabbit polyclonal antibody sc-482X (Santa Cruz Biotechnology, Inc.); anti-pSTAT3-Y705 mouse monoclonal antibody sc-8059X (Santa Cruz Biotechnology, Inc.); and anti-GAPDH mouse monoclonal antibody ab8245 (Abcam). ChIP-sequencing was performed with the anti-STAT3 antibody sc-482X on formaldehyde-crosslinked pellets of 1 × 10⁶ cells. DNA was mechanically sheared using a Branson sonicator, then immunoprecipitated for 16 hr. Bound DNA was recovered on protein A-agarose beads and purified via ethanol precipitation. mRNA for RNA-sequencing was isolated directly from whole cell lysate using magnetic poly-dT beads (Dynabeads mRNA DIRECT Kit; Invitrogen), then chemically fragmented (RNA Fragmentation Reagents; Ambion), cDNA was synthesized using random hexamer primers. For library preparation, standard Illumina GA-IIx primers were ligated and gel purification was used to size-select DNA in the 150- to 300-bp range. Single-ended 36-bp reads were generated for both ChIP- and RNA-sequencing runs.

Statistical analysis

Sequencing results were mapped to the human genome (hg19) using Bowtie (Langmead et al. 2009). STAT3 ChIP-sequencing peaks were compared with a non-IP'd genomic DNA control, and identified using the SPP peak caller (Kharchenko et al. 2008). Replicates were analyzed using irreproducible discovery rate analysis to identify strong, repeatable peaks for each cell line (Li et al. 2011). These lists were combined and any overlapping or abutting peaks were merged into broader BRs (Kasowski et al. 2010). BRs that occurred in only one cell line were eliminated from further analysis. The ChIP-sequencing data for each line were rescored to determine how many fragments mapped to each BR. RNA-sequencing mapped reads were intersected with the RefSeq database to generate read counts for each annotated gene. Both data sets were then normalized to library size with DESeq, and to contrast the two subtypes, the DESeq parameterized negative binomial model was used to obtained the P-values for each BR or gene (Anders and Huber 2010). To correct for multiple comparisons, P-values were adjusted with the Benjamini-Hochberg procedure (Benjamini and Hochberg 1995). ChIP-Seq BRs were associated with genes that they might regulate via the Genomic Regions Enrichment of Annotations Tool using its default association settings (GREAT; McLean et al. 2010). This list of genes associated with significant changes in STAT3 binding was compared with the list of genes with significant expression changes using the online tool Galaxy (Giardine et al. 2005; Blankenberg et al. 2010; Goecks et al. 2010). Extended materials and methods are available as Supporting Information, File S1, complete data tables are available as File S2. All ChIP-Seq and RNA-Seq data are available in the NCBI GEO public database as series accession no. GSE50724. Within this accession, ChIP-Seq data are found in the subseries GSE50723, and RNA-Seq data are in the subseries GSE50721. Individual data files are assigned the consecutive accession numbers GSM1227193-GSM1227214.

RESULTS AND DISCUSSION

STAT3 is overexpressed and overactive in ABC DLBCL

In normal B-cells, STAT3 is expressed at low endogenous levels in the cytosol. High levels of STAT3 expression and activation frequently are found in ABC DLBCL, suggesting that it plays a major role in the oncogenesis of this subtype (Ding et al. 2008; Wu et al. 2011). To investigate the levels of activation of STAT3 in the treatment-responsive GCB lymphoma relative to ABC lymphoma, we selected eight patient tumor–derived cell lines for study and examined levels of total and activated STAT3 by using immunoblot analysis. Four of these cell lines have been classified by Drexler (2010) as GCB (SU-DHL4, SU-DHL6, SU-DHL10, OCI-Ly7) and four as ABC (SU-DHL2, OCI-Ly3, OCI-Ly10, U-2932).

Whole-cell lysates from each line were prepared and probed with antibodies that recognize total STAT3 as well as those that recognize only the phosphorylated (Tyr705) activated form (Shuai et al. 1993; Wen et al. 1995; Zhang et al. 1995). STAT3 protein is present in all of the GCB and ABC cell lines; however, it is at much greater levels (7.2-fold) in all four ABC cell lines (Figure 1). Furthermore, the phosphorylated form of the protein exhibits an even larger difference (56-fold) between the GCB and ABC lines (Figure 1).

STAT3 shows differential binding in ABC relative to GCB cells

To better understand how STAT3 induces aggressive behavior in ABC cells, we next sought to determine the chromosomal targets of STAT3 in all eight cell lines. We performed ChIP-Seq by using an antibody prepared against the protein’s C-terminal region, the area most divergent among STAT family proteins (Baker et al. 2007). Immunoblot analyses indicate that this antibody recognizes a single band of the expected molecular mass, which was confirmed as STAT3 by immunoprecipitation followed by mass spectrometry (see Figure S1). We

Figure 1 Western blot analysis of STAT3 in ABC and GCB cell lines. Western immunoblots were performed on whole-cell lysate from DLBCL cell lines probed with antibodies against STAT3, tyrosine-phosphorylated STAT3, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Fold change was measured by densitometric quantification using NIH ImageJ software, normalized to a GAPDH loading control.
performed ChIP-Seq for all eight cell lines along with genomic DNA input controls. Two to nine biological replicates were carried out for each line; replicates were sequenced to an average depth of 18 million mapped reads (87% mapping; see Table S1). All replicates were used in the analysis.

The ChIP-Seq binding peaks were scored using the SPP peakcaller and irreproducible discovery rate analysis (Kharchenko et al. 2008; Li et al. 2011), which resulted in the identification of 1000–6500 strongly reproducible peaks per cell line (Table 1). Overlapping or abutting peaks were merged into BRs to facilitate comparison between cell lines, yielding a total of 10,337 distinct STAT3 BRs that are occupied in at least two of the eight cell lines. These BRs occur throughout the genome, with no obvious hot spots.

To identify target regions differentially bound by STAT3 in the ABC and GCB subtypes, we used the parameterized negative binomial model in DESeq (Anders and Huber 2010) to identify those BRs that displayed significantly different normalized fragment counts between the ABC and GCB cell lines, then corrected for multiple comparisons using the Benjamini-Hochberg procedure (Benjamini and Hochberg 1995). Of the 10,337 high-confidence BRs, one third (n = 3524) are differentially bound by STAT3 between the two subtypes at a false-discovery rate (FDR) < 0.05. (For a complete list of peaks by enriched subtype, see Table S4.) When these differentially bound peaks are clustered, the DLBCL cell lines cluster according to their GCB-ABC subtype (Figure 2). Consistently, more BRs are strongly bound in ABC than in GCB, although BRs with increased STAT3 binding occur surprisingly frequently in the GCB cell lines given their low level of STAT3 expression: 44% of differentially bound BRs (n = 1550) show more STAT3 binding in GCB, whereas 56% (n = 1974) are more strongly bound in ABC (Figure 3A). STAT3 protein levels are very low in GCB cell lines, so one possible explanation for its equivalent number of binding sites is simply that they represent lower occupancy regions. Indeed, we noticed the signal strength for the GCB lines was lower than that of the ABC cell lines and required additional ChIP-Seq replicate experiments to identify peaks.

STAT3 has a binding peak 14 bp upstream of the transcription start site (TSS) of JAK3, and this binding is much stronger (fold change = 12.47, FDR = \(5.21 \times 10^{-7}\)) in the ABC subtype (Figure 3B). JAK3 associates with the interleukin (IL)-2 family γ-chain receptors, transducing the signal from cytokines such as IL-2, IL-7, IL-9, IL-15, and IL-21 (Suzuki et al. 2000). Although JAK2 is often regarded as the primary partner of STAT3, constitutively active JAK3:STAT3 signaling has been reported as a poor prognosis indicator in anaplastic lymphoma (Liang et al. 2012), suggesting that eIF-3B may also play a role in GCB DLBCL.

Conversely, EIF3B shows increased STAT3 binding in the GCB subtype cell lines (fold change = 0.01, FDR = \(2.21 \times 10^{-3}\); Figure 3B). As with JAK3, the STAT3 binding peak is just upstream of the TSS, a common location for gene regulation by transcription factors. EIF3B is a major scaffolding subunit of the eukaryotic translation initiation factor 3 (eIF-3) complex, a complex required for the initiation of protein synthesis. Intriguingly, short hairpin RNA knockdown of eIF-3B induces apoptosis in glioblastoma (Liang et al. 2012), suggesting that eIF-3B may also play a role in GCB DLBCL.

**Table 1** STAT3 peaks identified by IDR analysis by cell line

| Name          | Peaks by IDR |
|---------------|--------------|
| ABC cell lines|              |
| SU-DHL2       | 5375         |
| OCI-Ly3       | 2885         |
| OCI-Ly10      | 3258         |
| U-2932        | 5180         |
| GCB cell lines|              |
| SU-DHL4       | 6535         |
| SU-DHL6       | 4570         |
| SU-DHL10      | 1067         |
| OCI-Ly7       | 6262         |

**Table 2** Hierarchical clustering analysis of STAT3 BRs. Clustering was performed on the 3524 regions that are differentially bound by STAT3 at FDR < 0.05 in ABC cell lines vs. GCB cell lines. Green and red blocks, respectively, represent high and low number of fragments sequenced in that BR relative to the average, whereas black blocks indicate no difference in expression. Fragment counts were log transformed to approximate a normal distribution, standardized by cell line, and each BR was normalized with sum of squares set to unity. GCB cell lines are represented by orange bars and ABC cell lines by blue bars. Generated using the heatmap.2 function in the R package gplots (R Development Core Team 2008; Warnes et al. 2011).

**Figure 2** Hierarchical clustering analysis of STAT3 BRs. Clustering was performed on the 3524 regions that are differentially bound by STAT3 at FDR < 0.05 in ABC cell lines vs. GCB cell lines. Green and red blocks, respectively, represent high and low number of fragments sequenced in that BR relative to the average, whereas black blocks indicate no difference in expression. Fragment counts were log transformed to approximate a normal distribution, standardized by cell line, and each BR was normalized with sum of squares set to unity. GCB cell lines are represented by orange bars and ABC cell lines by blue bars. Generated using the heatmap.2 function in the R package gplots (R Development Core Team 2008; Warnes et al. 2011).

**Table 3** Gene Ontology Biological Processes (GO BP) ontology:

| Gene name | Description |
|-----------|-------------|
| EIF3B     | Protein with regulatory function in translation initiation factor 3 (eIF-3) complex, a complex required for the initiation of protein synthesis. |
to the ABC subtype (Angelin-Duclos et al. 2000; Falini et al. 2000; Fornek et al. 2006; Avery et al. 2010). The Disease Ontology analysis reveals that the 1974 ABC-enriched STAT3 BRs fall near genes associated with many forms of cancer, especially lymphomas and leukemias (Figure 4C).

Although there are nearly as many STAT3 BRs with strong binding in the GCB cell lines as in the ABC lines, these BRs and their associated genes do not point to a clear oncogenic program like the ABC BRs do. Far fewer categories are enriched, and at lower significance levels; furthermore, the 1550 GCB-specific BRs are not enriched for any disease categories. The enriched PANTHER Pathway category “apoptosis signaling pathway” primarily contains genes that induce apoptosis for the GCB-bound BRs, but the ABC subtype list includes genes that both up- and down-regulate apoptosis (Figure 4B). Taken together, these data show that in the ABC subtype, overactive STAT3 substantially changes its binding behavior and promotes a genetic program that blocks apoptotic signaling.

**STAT3 binding sites in DLBCL are seen in other hematopoietic and cancer cell lines:** We compared the overall list of STAT3 BRs found in DLBCL with BRs identified in three other cell lines: GM12878, an EBV-transformed B lymphocyte line; HeLa S3, a suspension-tolerant clonal derivative of the HeLa cervical adenocarcinoma line; and LoVo, a colorectal adenocarcinoma cell line. GM12878 and HeLa S3 experiments were performed as part of the ENCODE project (The ENCODE Project Consortium et al. 2011) as GEO nos. GSM935557 and GSM935276, whereas the LoVo experiments were performed by Yan et al. (2013) as GEO no. GSM1208799.

On the basis of a 1-bp overlap, 3932 (38%) of the 10,337 STAT3 BRs observed in our DLBCL cell lines are also found in GM12878 cells, whereas 1143 (11%) are found in LoVo and 1063 (10%) in HeLa S3 (see Figure S2). It is not surprising that GM12878 has the greatest concordance with DLBCL, as it is the most similar cell type. DLBCL and GM12878 share 2958 BRs not found in either HeLa S3 or LoVo. As determined using GREAT (McLean et al. 2010), these BRs are found near genes enriched for type 1 interferon and cytokine signaling, many B-cell properties including activation and differentiation, DNA damage response, and the JAK/STAT pathway itself (including JAK1 and JAK3; STAT1, 3, 4, 5A, and 5B; and the down-regulators SOCS1, PIAS2, and PTPRC). More than one-third (36%, n = 1406) of these regions are subtype-specific in DLBCL, and three quarters of these (74%, n = 1049) are more strongly bound in the ABC subtype. This bias toward ABC regions may be due to the presence of the Epstein-Barr virus used to transform GM12878; EBV is a well-known oncovirus that promotes the development of hematopoietic cancers (Pallesen et al. 1991; Yu et al. 1996; Siu et al. 2002; Brady et al. 2007; Castillo et al. 2008) and whose presence contributes to poorer survival in DLBCL specifically (Park et al. 2007).

The 1063 STAT3 binding sites shared between DLBCL and HeLa S3 are enriched for genes involved in a number of cancer-related functions: chromatin structure, single-stranded DNA binding, DNA damage checkpoints, abnormal interferon levels, and the apoptotic signaling pathway. One third (n = 353) of these regions are subtype-specific in DLBCL, and the vast majority (90%, n = 316) are more strongly bound in the ABC subtype. The ABC-specific BRs in HeLa S3 and GM12878 fall near genes that enrich many of the same ontological categories, including immune response, the JAK/STAT pathway, interferon signaling and response, and cytokine signaling and response. They also share Disease Ontology categories that indicate immune system activation, such as leukemias of various types, allergies, hepatitis, and response to infection. In contrast, the 1143 shared LoVo BRs are primarily enriched for genes involved in RNA processing, splicing, and translation, rather than cancer-related categories. Bias toward ABC-specific BRs is not seen in the LoVo colon carcinoma line, where BRs specific to each DLBCL subtype are equally represented. Only 143 STAT3 BRs are found in all four cell types. These are generally not near genes enriched for any pathways or ontological categories. However, there is overlap with a curated gene sets for genes that are targets of c-Myc.

**Subtypes show differential gene expression**

To better understand the biology of the GCB and ABC subtypes and to relate their gene expression profiles to identified STAT3 targets, we examined global mRNA expression in both subtypes using RNA-Seq analysis (Morin et al. 2008). RNA-Seq was performed on mRNA isolated from all eight cell lines. Two biological replicates per cell line were analyzed with an average of 22 million mapped reads (86% mapping; see Table S2).

To identify genes that are differentially expressed in each subtype, we used the parameterized negative binomial model in DESeq (Anders and Huber 2010) to identify annotated RefSeq genes that displayed significantly different normalized read counts between the
ABC and GCB cell lines, then corrected for multiple comparisons by using the Benjamini-Hochberg procedure (Benjamini and Hochberg 1995). We found many genes that exhibit differential gene expression in the GCB and ABC cell types, including several genes that play a role in apoptosis and cancer. This analysis also successfully re-identified many genes that have previously been shown to be biomarkers for each DLBCL subtype (Rosenwald et al. 2002; Tirado et al. 2012), including BCL2, IRF4, MME (CD10), and BCL6 (Table 2). Surprisingly, the established ABC subtype biomarker MUM1 (Hans et al. 2004; Sweetenham 2005; Anderson et al. 2009) showed no significant expression change (FDR = 0.92) but did have a STAT3 BR 344 bp upstream of its TSS with significantly more binding in GCB (fold change = 0.46, FDR = 4.89 × 10⁻³).

A total of 1545 genes are differentially expressed between subtypes at an FDR < 0.05 (Figure 5), which is approximately 7% of the transcriptome. The vast majority of these genes (81%, n = 1251) are more highly expressed in the ABC cell lines. In contrast, only 294 genes (19%) are more highly expressed in the GCB cell lines. Interestingly, half (n = 765) of the genes with greater ABC subtype expression demonstrate very low read counts (<5) in the GCB cell types. Conversely, only 21 genes that are more highly expressed in GCB are unique to that subtype (Figure 6A). The prevalence of such “on/off” genes indicates that the major differences between ABC and GCB DLBCL are due almost exclusively to additional gene expression in ABC, rather than the two subtypes having divergent but equally active genetic programs.

**Genes up-regulated in ABC subtype:** Genes with GO BP categories related to cell adhesion, motility, and chemotaxis are enriched in ABC DLBCL cells relative to GCB cells (Figure 7). The expression of these pathways would prime tumors to spread rapidly from their lymph nodes of origin, and may partially explain why ABC lymphomas are so much more aggressive than their GCB counterparts.

The underlying gene list includes a large number of chemokine ligands and receptors, including several with known roles in cancer (Table 3). CCR7 shows expression limited to the ABC subtype (Figure 6B). Increased CCR7 expression is clearly associated with metastasis to...
the lymph nodes in a broad variety of cancers (Schimanski et al. 2006; Kodama et al. 2007; Nakata et al. 2008; Pan et al. 2008; Arigami et al. 2009; Ishida et al. 2009). Furthermore, CCR7 and CXCR5 contribute to apoptosis resistance in B-cell–derived acute and chronic lymphocytic leukemia (Hu et al. 2004; Burkle et al. 2007).

Also up-regulated in the ABC subtype is transforming growth factor alpha (TGFA), which is a ligand for the epidermal growth factor receptor. Epidermal growth factor receptor in turn activates a signaling pathway for cell proliferation, differentiation, and development that significantly affects the progression of many human cancers, including brain, lung, breast, ovarian, prostate, and pancreatic tumors (Lu et al. 2011).

Genes in GO BP categories related to angiogenesis and hypoxia are also substantially enriched in the ABC cell lines (Figure 7). Angiogenesis is known to be important and prognostic in malignant lymphomas (Koster and Raemaekers 2005). The factors up-regulated in ABC DLBCL include FGF2, a major lymphangiogenic growth factor that promotes tumor growth and metastasis (Cao et al. 2008; Da et al. 2008). A number of growth stimulation factors and receptors are also up-regulated, such as platelet-derived growth factor alpha (PDGFA) and the beta subunit of the PDGF receptor (PDGFRB), both of which play essential roles in blood vessel development. Hypoxia induced genes include ARNT2, which has been reported to promote VEGF expression in teratomas and to protect neuronal cells from hypoxia (Maltepe et al. 2000). ARNT2 expression has not been reported previously as a mechanism in non-Hodgkin lymphoma. Thus, these analyses suggest new molecules that may be involved in ABC tumorigenesis.

### Genes up-regulated in GCB subtype

GO analysis of the differentially expressed genes reveals that the GCB-enriched transcripts are involved in activation of lymphocytes (Figure 7). This list includes BCL6, a major biomarker for the GCB DLBCL subtype. Another notable GCB up-regulated gene is protein kinase C alpha (PKCα), which is encoded by PRKCA (Figure 6B). PKCα is a protein kinase that can act as an oncogene (Besson and Yong 2000; Huttemann et al. 2012). However, in response to inflammatory signaling, PKCα can negatively regulate NF-κB–induced genes by promoting the synthesis of the inhibitor IκBα (Han et al. 1999). Constitutive NF-κB signaling is a prominent feature of ABC DLBCL and includes crosstalk with STAT3 via up-regulation of IL-6 and IL-10 (Motoyama et al. 2005). The high PKCα and low NF-κB levels in our GCB cell lines suggests that its predominant role in DLBCL may not be as an oncogene but rather as an inhibitor of the NF-κB pathway.

### STAT3 induces an aggressive genetic program in DLBCL

To better understand the downstream consequences of STAT3 binding, we next integrated the binding and gene expression results. Genes associated with STAT3 BRs were correlated with their

Table 2: Validated DLBCL subtype signature genes

| Gene Name       | Gene Description                                      | GCB Read Counts | ABC Read Counts | Fold Change | FDR        |
|-----------------|-------------------------------------------------------|-----------------|-----------------|-------------|------------|
| **ABC signature** |                                                       |                 |                 |             |            |
| BCL2            | B-cell CLL/lymphoma 2                                 | 4,599.52        | 22,162.49       | 4.82        | 4.90E-05   |
| CCND2           | Cyclin D2                                             | 31.20           | 3692.67         | 118.60      | 1.56E-18   |
| CFLAR           | CASP8 and FADD-like apoptosis regulator                | 460.63          | 6463.37         | 14.03       | 5.52E-09   |
| FOXP1           | forkhead box P1                                       | 1202.37         | 6588.56         | 5.46        | 1.13E-04   |
| IRF4            | Interferon regulatory factor 4                         | 976.01          | 21,475.28       | 22.01       | 2.43E-14   |
| NFKBIZ          | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta | 962.34          | 8119.55         | 8.46        | 5.63E-06   |
| **GCB signature** |                                                       |                 |                 |             |            |
| BCL6            | B-cell CLL/lymphoma 6                                 | 15,105.68       | 5124.25         | 0.34        | 1.94E-02   |
| MAPK10          | Mitogen-activated protein kinase 10                   | 1473.10         | 57.42           | 0.04        | 4.45E-05   |
| MME (CD10)      | Membrane metallo-endopeptidase                        | 6163.64         | 663.16          | 0.11        | 6.01E-05   |
| MYBL1           | v-myb myeloblastosis viral oncogene homolog (avian)-like 1 | 2932.21         | 661.39          | 0.23        | 4.99E-02   |

DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like; ABC, activated B-cell-like; FDR, false-discovery rate; CLL, chronic lymphocytic leukemia.
expression levels from the RNA-Seq data. Both the STAT3 binding and mRNA expression were evaluated for statistical significance, resulting in a list of genes that shows both nearby STAT3 binding changes and an accompanying relative mRNA expression level for the two cell types.

ChIP-Seq identified a total of 10,337 STAT3 BRs, whereas the RNA-Seq analysis compared the expression level of 20,992 genes. Using GREAT analysis, we found that more than half of these genes (60%, n = 12,631) have a STAT3 BR associated with them. Many of these genes have multiple nearby BRs; likewise, many BRs are associated with two genes because they are located in a region in which putative regulatory domains overlap. Intersecting the ChIP-Seq and RNA-Seq datasets resulted in a total of 16,341 gene/BR matches (see Table S4). Forty percent (n = 6580) showed significant differences (FDR, 0.05) in at least one category: either gene expression or STAT3 binding differed markedly between the two DLBCL subtypes. A total of 823 of these gene/BR matches, corresponding to 445 individual genes, were significantly different in both categories (Figure 8).

If STAT3 binding did not influence DLBCL gene expression, we would expect the nature of STAT3 binding near a gene to have no correlation with its expression level (Zhu et al. 2012). Instead, we observe that an increase in STAT3 binding is correlated with an increase in expression in most of these pairs (83%, n = 686), an association that is highly significant at $P = 2.3 \times 10^{-28}$ (Table 4). The strong association between binding and increased expression indicates that STAT3 binding is a significant contributor to the gene expression pattern in GCB and ABC DLBCL. The analysis indicates that STAT3 primarily functions as a transcriptional activator whereas a subset of its binding might contribute to transcriptional repression, which is consistent with its roles as previously described (Ouyang et al. 2009).

High STAT3 binding and gene expression in ABC: The most enriched category of BR/gene pairs consists of genes with greater STAT3 binding in the ABC subtype as well as increased gene expression in ABC. 531 pairs correspond to 287 different genes. STAT3 itself is among these, as are several of its known targets, including PRDM1 and SOCS3 (Table 5). We also confirm the findings from array CGH studies that NFKB1 and the oncogene PIM2 are elevated in ABC lymphoma (Tirado et al. 2012), but with the added information that STAT3 shows elevated levels of binding in the regulatory domains of these genes.

STAT3 also binds near many genes that are up-regulated in ABC cells relative to GCB cells; these genes have a wide range of functions that are pertinent to oncogenesis, especially apoptosis and cellular signaling. The CXCR5 chemokine receptor, which contributes to apoptosis resistance in B-cell—derived leukemias, is 6.83-fold more expressed in the ABC subtype (FDR = 8.83 × $10^{-7}$) and also has a distinct STAT3 peak 43 bp upstream of its TSS that is occupied only in ABC cell lines (Figure 9). STAT3 is also characterized as regulating the BCL2 protein family, which influences apoptosis. We specifically identify BCL2A1 (formerly BFL1), which is associated with three strongly bound STAT3 BRs and demonstrates a 4.43-fold increase in expression. High levels of BCL2A1 have been proposed as a mechanism of chemoresistance in chronic lymphocytic leukemia (Olsson et al. 2007).
STAT3 also has a binding peak just 7 bp upstream of the TSS of BATF, which is highly expressed in ABC cells. BATF belongs to the AP-1/ATF superfamily of transcription factors and dimerizes with the Jun family, acting as a negative regulator (Echlin et al. 2000). Although BATF typically promotes growth arrest and terminal differentiation (Liao et al. 2011a), chronically elevated BATF levels often are seen in lymphoid tumors and promote an impaired response to apoptotic signals, apparently mediated by the BCL2 family (Logan et al. 2012). Because normal levels of BATF stop cell division, this pathway presents a compelling target for drug modification.

We also identify APOL2 as a potential target of STAT3, suggesting a novel mechanism of apoptosis resistance in ABC DLBCL cells. A STAT3 BR is located 322 bp downstream of the APOL2 TSS (fold change = 2.64, FDR = 2.44 × 10^{-6}), and its mRNA expression level rises 36.76-fold in the ABC subtype (FDR = 6.80 × 10^{-3}). APOL2 has recently been found to protect endothelial cells from IFNγ cytotoxic signaling (Liao et al. 2011b), and could play the same role in DLBCL in response to inflammatory signals.

Many interleukins and interleukin receptors show both elevated expression and STAT3 binding, including IL-6, IL-10, IL-10RA, and IL-12A. Both IL-6 and IL-10 are known to induce signaling via STAT3 upon binding their extracellular receptors; in turn, STAT3 up-regulates expression of the IL-10 and IL-6 genes to form an activation loop. NFKBIZ, which is also upregulated by STAT3, is a nuclear IκB protein that activates IL-6 transcription and may also play a role in this loop (Motoyama et al. 2005). Polymorphisms in IL-10 and its receptor subunit IL-10RA, also up-regulated in this study, have been implicated in the development of non-Hodgkin lymphoma generally and B-cell lymphoma specifically (Lan et al. 2006; Rothman et al. 2006), suggesting that IL-10 pathway dysregulation promotes hematopoietic tumors.

IL-2RB produces the beta subunit of the IL-2 cytokine receptor. Its expression level increases 935.76-fold from GCB to ABC (FDR = 6.45 × 10^{-16}) and is associated with increased STAT3 binding at a distal site about 27 kb downstream (FDR = 1.33 × 10^{-19}). IL-2RA, which encodes the other half of the IL-2 receptor complex, is also up-regulated in the ABC subtype, although it lacks a proximal STAT3 peak (fold change = 8.00, FDR = 1.95 × 10^{-2}). These findings point to a potential therapy target for refractory cases of ABC DLBCL. The existing anticancer treatment denileukin difitox (trade name Ontak) is an engineered protein combining IL-2 and diphtheria toxin, which binds to IL-2 receptors and introduces the diphtheria toxin into cells, killing them (Lansigan et al. 2010). Ontak has been specifically approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma but should be effective in treating any lymphoma that displays an elevated number of IL-2 receptors. Furthermore, increased expression of the IL-2RB gene is known to increase the efficacy of Ontak treatment (Shao et al. 2002).

**High STAT3 binding and gene expression in GCB:** A total of 95 genes have greater STAT3 binding and gene expression in GCB cells. Among these are MYBL1, a known biomarker for the GCB subtype (Blenk et al. 2007), which is overexpressed as expected in GCB cell lines and also has a statistically significant STAT3 peak 199 bp upstream of its TSS. Also included in this list are two tumor suppressor genes: ABI3 and TRIB2. In thyroid tumors, ABI3 expression blocks tumor progression on many fronts, including reducing anchorage-independent growth and in vivo tumor formation while increasing cellular senescence (Latini et al. 2011). In the GCB subtype, it demonstrates greater expression that corresponds to the presence of STAT3 424 bp downstream of its TSS (Figure 9). TRIB2 inhibits admission of CD4+ T cells to tumors and thus may help limit the immune surveillance of these tumors.

**Table 3 Selected differentially expressed genes**

| Gene Name | Gene Description | GCB Read Counts | ABC Read Counts | Fold Change | FDR   |
|-----------|------------------|-----------------|-----------------|-------------|-------|
| ABC up    |                  |                 |                 |             |       |
| ARNT2     | Aryl-hydrocarbon receptor nuclear translocator 2 | 0.00            | 386.14          | N/A         | 2.25E-08 |
| CCR7      | Chemokine (C-C motif) receptor 7 | 46.30           | 8,252.02        | 178.25      | 4.72E-23 |
| CXCR5     | Chemokine (C-X-C motif) receptor 5 | 1,845.20        | 12,595.47       | 6.83        | 8.83E-07 |
| FGFR2     | Fibroblast growth factor 2 (basic) | 5.23            | 149.82          | 28.63       | 1.34E-02 |
| PDGFA     | Platelet-derived growth factor alpha polypeptide | 3.25            | 106.66          | 32.83       | 1.59E-02 |
| PDGFRB    | Platelet-derived growth factor receptor, beta polypeptide | 0.43            | 26.39           | 60.79       | 1.62E-02 |
| TGFA      | Transforming growth factor, alpha | 4.50            | 132.35          | 29.42       | 2.46E-02 |
| GCB up    |                  |                 |                 |             |       |
| BCL6      | B-cell CLL/lymphoma 6 | 15,105.68       | 5,124.25        | 0.34        | 1.94E-02 |
| PRKCA     | Protein kinase C, alpha | 5,600.83        | 1,531.13        | 0.27        | 5.00E-04 |

GCB, germinal center B-cell-like; ABC, activated B-cell-like; FDR, false-discovery rate; N/A, not available; CLL, chronic lymphocytic leukemia.

---

**Figure 8** STAT3 binding correlated with gene expression change. Red dots indicate STAT3 BRs that have significant differences in binding (FDR < 0.05) between subtypes and are also associated with genes that display significant differences in expression (FDR < 0.05); dark gray dots indicate STAT3 BRs that either show significant differences in binding or whose associated genes display a significant difference in expression; and light gray dots indicate other BRs.
JNK, which ultimately reduces the antiapoptotic activity of BCL2 (Gilby et al. 2010). The loss of TRIB2 expression in ABC DLBCL is particularly problematic, as STAT3 increases the expression of BCL2 and its family members.

**Anticorrelated STAT3 binding and gene expression:** Seventeen percent (n = 137) of BR/gene pairs have strong STAT3 binding in one subtype but strong gene expression in the other. These 107 genes may be regulated by other factors, or STAT3 may serve as a repressor at these sites, potentially by blocking the binding of other factors. Fully 40% (n = 43) of these potential anticorrelated genes occur due to a mixture of STAT3 binding behavior: the gene is associated with many BRs, some of which are more occupied by STAT3 in ABC while others show stronger binding GCB.

We observe greater CD22 expression in GCB DLBCL, associated with a STAT3 peak 138 bp upstream of its TSS. However, CD22 also has two STAT3 BRs near its 3' end that are more strongly bound in ABC (Figure 9). This finding suggests that STAT3 binding at the CD22 promoter drives transcription, whereas binding at the two downstream sites suppresses it. CD22 is a cell surface antigen expressed in a wide variety of non-Hodgkin lymphomas, and anti-CD22 monoclonal antibody treatments currently are being developed (Lu et al. 2006; Li et al. 2013). However, they may be less successful in treating ABC DLBCL due to lowered expression of this antigen.

BCL6 is the most extreme example of this mixed binding phenomenon. It is the primary biomarker for the GCB subtype of DLBCL and is known to be regulated by STAT3. We found that expression of BCL6 is extremely high in GCB lines, three times the level found in our ABC cell lines. However, its regulation is complex: there are 24 STAT3 BRs within the putative regulatory domain of BCL6, which includes a large upstream gene desert that contains considerable STAT3 binding activity. Seven of these BRs show a significant binding differential between the subtypes. Two of them are more strongly bound in ABC, but the other five are more strongly bound by STAT3.

**Table 4 STAT3 binding is correlated with gene expression by the χ² test**

| STAT3 Binding | Gene Expression | Expected Frequency | Expected Counts | Observed Counts | $(\text{obs.} - \text{exp})^2$/exp |
|---------------|-----------------|--------------------|-----------------|-----------------|---------------------------------|
| ABC+          | ABC+            | 55% • 81% = 46.5%  | 382             | 531             | 57.19                           |
| ABC+          | GCB+            | 55% • 19% = 9.5%   | 78              | 64              | 2.51                            |
| GCB+          | ABC+            | 45% • 81% = 36.5%  | 300             | 155             | 70.08                           |
| GCB+          | GCB+            | 45% • 19% = 7.5%   | 61              | 73              | 1.95                            |

χ² = 131.74
d.f. = 3
$P = 2.3 \times 10^{-28}$

**Table 5 Selected differentially expressed genes with associated STAT3 peaks**

| Gene Name | Peak Proximity to TSS | ChIP Fold Change | ChIP FDR | Expression Fold Change | Expression FDR |
|-----------|-----------------------|------------------|----------|------------------------|----------------|
| Increased ABC binding and expression | | | | | |
| APOL2     | 322                   | 2.64             | 2.44E-06 | 36.76                  | 6.80E-14       |
| BATF      | −7868                 | 4.14             | 2.50E-14 | 18.51                  | 5.48E-10       |
| STAT3     | −308                  | 5.50             | 3.07E-19 | 21.56                  | 3.25E-09       |
| BCL2A1    | −37                   | 3.73             | 4.97E-13 | 18.51                  | 5.48E-10       |
| BCL2A1    | −6328                 | 5.58             | 5.14E-07 | 21.56                  | 3.25E-09       |
| BCL2A1    | 59                    | 2.69             | 1.54E-06 | 21.56                  | 3.25E-09       |
| CXCR5     | −43                   | 3.29             | 4.84E-07 | 6.82                   | 8.83E-07       |
| IL-6      | −28625                | 2.79             | 1.96E-07 | 10369.08               | 7.03E-05       |
| IL-10     | 5883                  | 2.45             | 7.48E-04 | 228.86                 | 2.37E-11       |
| IL-10RA   | 917                   | 2.00             | 1.91E-03 | 4.96                   | 7.26E-04       |
| IL-12A    | −63                   | 2.41             | 9.49E-05 | 28133.47               | 2.60E-07       |
| IL-2RB    | 27623                 | 4.69             | 1.33E-19 | 935.76                 | 6.45E-16       |
| SOCS3     | −65                   | 9.45             | 2.66E-33 | 1251.98                | 2.14E-15       |
| STAT3     | −308                  | 17.63            | 1.05E-09 | 9.00                   | 1.39E-07       |
| PIM2      | −25                   | 1.78             | 2.74E-03 | 12.30                  | 2.78E-10       |
| PRDM1     | 11587                 | 2.17             | 1.16E-03 | 127.12                 | 3.21E-16       |
| NFKBIZ    | −95                   | 4.59             | 7.14E-16 | 8.46                   | 5.63E-06       |
| Increased GCB binding and expression | | | | | |
| AB13      | 424                   | 0.61             | 4.9E-02  | 0.19                   | 2.55E-02       |
| MYBL1     | −199                  | 0.66             | 3.48E-02 | 0.23                   | 4.99E-02       |
| TRIB2     | −144                  | 0.37             | 6.71E-06 | 0.07                   | 6.81E-08       |
| Mixed binding and expression | | | | | |
| CD22      | −138                  | 0.30             | 1.21E-07 | 0.25                   | 8.10E-04       |
| CD22      | 17,622                | 2.91             | 8.27E-09 | 0.25                   | 8.10E-04       |
| CD22      | 18,556                | 4.65             | 7.74E-11 | 0.25                   | 8.10E-04       |
in GCB (see Figure S3 and Table S3). This complexity suggests that the overall sum of STAT3 binding contributes to the final regulation of BCL6.

The combination of whole-genome profiling approaches shows differential STAT3 binding sites near almost a third of all genes that differ in expression between GCB and ABC DLBCL, leaving little doubt that STAT3 is a regulator of the aggressive clinical phenotype and drug resistance displayed by the ABC subtype. The STAT3 binding and expression results suggest possible models by which STAT3 regulates biological pathways to promote aggressive oncogenic behavior in ABC DLBCL. Ontological analysis of the genes up-regulated in ABC DLBCL with increased nearby STAT3 binding indicates that STAT3 promotes cell migration, blood vessel development, and the inflammatory response (Figure 10). Furthermore, it ensures its own continued high expression by up-regulating its pathway partners and upstream signaling molecules, such as IL-6 and IL-10, and promotes cross-talk with the nuclear factor-κB pathway. Most critically, STAT3 strongly up-regulates many mechanisms of apoptosis resistance. These effects synergize and likely lead to increased cell proliferation and distributions of cells, which are hallmarks of aggressive lymphomas. These results provide novel insights into the genetics of oncogenesis in the ABC form of diffuse large B-cell lymphoma and identify a substantial number of plausible downstream mechanisms for the treatment-resistant phenotype of this subtype.

Figure 9 STAT3 peaks associated with gene expression changes. Examples of differentially occupied STAT3 BRs are shown. Blue tracks represent gene expression; orange tracks represent STAT3 binding; pink bars show noteworthy STAT3 BRs. CXCR5 shows increased gene expression correlated with STAT3 binding (chr11: 118,754,259–118,754,737) in the ABC cell lines: SU-DHL2, OCI-Ly3, OCI-Ly10, and U-2932. ABI3 shows strong increased gene expression correlated with STAT3 binding (chr17: 47,287,858–47,288,168) in the GCB cell lines: SU-DHL4, SU-DHL6, SU-DHL10, and OCI-Ly7. CD22 shows increased gene expression in the GCB cell lines, but a mixture of STAT3 binding behavior: STAT3 has more GCB binding near the TSS (chr19: 35,819,821–35,820,060) but more ABC binding at two sites near the 3' end (chr19: 35,837,564–35,838,866; chr19: 35,838,409–35,838,860).

Figure 10 Downstream pathways and genes induced by STAT3 in ABC DLBCL. Examples of the top GO Biological Processes categories enriched among genes with increased expression and increased STAT3 binding in ABC DLBCL. All P-values are corrected for multiple comparisons using the Benjamini-Hochberg procedure.
ACKNOWLEDGMENTS
We thank the ENCODE Consortium for generating some of the data and techniques used in this work. We would also thank the laboratories of Dr. Louis Staudt at the National Cancer Institute and Dr. Ash Alizadeh at the Stanford School of Medicine for the generous donation of some of the DLBCL cell lines used in these experiments. This research was supported in part by the National Institutes of Health “Analysis of Human Genome Using Integrated Technologies” Centers of Excellence in Genomic Science Award Grant no. P50 HG002357 and by the ENCODE Consortium under National Institutes of Health grant NIH 5U54 HG 004558.

LITERATURE CITED
Alizadeh, A. A., M. B. Eisen, R. E. Davis, C. Ma, I. S. Lossos et al., 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 803–811.
Alvarez, J. V., and D. A. Frank, 2004 Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol. Ther. 3: 1045–1050.
American Cancer Society, 2012 Cancer Facts & Figures—2012. American Cancer Society, Atlanta.
Anders, S., and W. Huber, 2010 Differential expression analysis for sequence count data. Genome Biol. 11: R106.
Anderson, J. J., S. Fordham, L. Overman, H. Dignum, K. Wood et al., 2009 Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. Int. J. Oncol. 35: 961–971.
Angelín-Duclos, C., G. Cattoretti, K. I. Lin, and K. Calame, 2000 Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 165: 5462–5471.
Ariagui, T., S. Natsugoe, Y. Uenosono, S. Yanagita, H. Arima et al., 2009 CCNY and CCNYB expression predicts lymph node status including micrometastasis in gastric cancer. Int. J. Oncol. 35: 19–24.
Avery, D. T., E. K. Deenick, C. S. Ma, S. Suryani, N. Simpson et al., 2010 B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207: 155–171.
Baker, S. J., S. G. Rane, and E. P. Reddy, 2007 Hematopoietic cytokine receptor signaling. Oncogene 26: 6724–6737.
Benekli, M., M. R. Baer, H. Baumann, and M. Wetzler, 2003 Signal transducer and activator of transcription proteins in leukemias. Blood 101: 2940–2945.
Benjaminii, Y., and Y. Hochberg, 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57: 289–300.
Bennon, A., and V. W. Yong, 2000 Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression. Mol. Cell. Biol. 20: 4580–4590.
Blankenberg, D., G. Von Kuster, N. Coraor, G. Ananda, R. Lazarus et al., 2010 Galaxy: a web-based genome analysis tool for experimentalists. Curr. Protoc. Mol. Biol. Jan: Chapter 19: Unit 19.10.1.
Blenk, S., J. Engelmann, M. Weniger, J. Schultz, M. Dittrich et al., 2000 Commitment of B lymphocytes to a plasma cell fate is associated with B-ATF protein kinase C alpha-induced cell cycle progression. Mol. Cell. Biol. 20: 4590–4594.
Da, M. X., Z. Wu, and H. W. Tian, 2008 Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch. Med. Res. 39: 365–372.
Ding, B. B., J. J. Yu, R. Y. Yu, L. M. Mendez, R. Shakhnovich et al., 2008 Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111: 1515–1523.
Drexler, H. G., 2010 Guide to Leukemia-Lymphoma Cell Lines. German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany.
Echlin, D. R., H. J. Tae, N. Mitin, and E. J. Taparovskiy, 2000 B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene 19: 1752–1763.
Falin, B., M. Fizzotti, A. Pucciniari, B. Bigerna, T. Marafioti et al., 2000 A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 93: 2084–2092.
Fornek, J. L., L. T. Tygrett, T. J. Waldschmidt, V. Poli, R. C. Rickert et al., 2006 Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 107: 1085–1091.
Fu, K., D. D. Weisenburger, W. W. Choi, K. D. Perry, L. M. Smith et al., 2008 Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J. Clin. Oncol. 26: 4587–4594.
Giardine, B., C. Riemer, R. C. Hardison, R. Burhans, L. Eliniski et al., 2005 Galaxy: a platform for interactive large-scale genome analysis. Genome Res. 15: 1451–1455.
Gilby, D. C., H. Y. Sung, P. R. Winship, A. C. Goodeve, J. T. Reilly et al., 2010 Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia. Immunol. Lett. 130: 115–124.
Goeccks, J., A. Nekrutenko, and J. Taylor, 2010 Galaxy: a comprehensive approach for supporting accessible, reproducible and transparent computational research in the life sciences. Genome Biol. 11: R86.
Han, Y., T. Meng, N. R. Murray, A. P. Fields, and A. R. Brasier, 1999 Interleukin-1−induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis. J. Biol. Chem. 274: 939–947.
Han, Y., M. H. Amin, B. Franko, C. Frantz, X. Shi et al., 2006 Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108: 2796–2803.
Hans, C. P., D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie et al., 2004 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275–282.
Hodge, D. R., E. M. Hurt, and W. L. Farrar, 2005 The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41: 2502–2512.
Hu, C., J. Xiong, L. Zhang, B. Huang, Q. Zhang et al., 2004 PEG10 activation by co-stimulation of CXC5R and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. Cell. Mol. Immunol. 1: 280–294.
Huttemmann, M., I. Lee, L. I. Grossman, J. W. Doan, and T. H. Sanderson, 2012 Phosphorylation of mammalian cytochrome c and cytochrome c oxidase in the regulation of cell destiny: respiration, apoptosis, and human disease. Adv. Exp. Med. Biol. 748: 237–264.
Ishida, K., M. Iwashashi, M. Nakamori, M. Nakamura, S. Yokoyama et al., 2009 High CCR7 mRNA expression of cancer cells is associated with lymph node involvement in patients with esophageal squamous cell carcinoma. Int. J. Oncol. 34: 915–922.
Kasowski, M., F. Grubert, C. Heffelfinger, M. Harinhan, A. Asabere et al., 2010 Variation in transcription factor binding among humans. Science 328: 232–235.
Kharchenko, P. V., M. Y. Tolstorukov, and P. J. Park, 2008 Design and analysis of ChIP-seq experiments for DNA-binding proteins. Nat. Biotechnol. 26: 1351–1359.
Kodama, J., T. Hasengawa, N. Kusumoto, T. Seki, Matsuo et al., 2007 Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann. Oncol. 18: 70–76.

Koster, A., and J. M. Raemaekers, 2005 Angiogenesis in malignant lymphoma. Curr. Opin. Oncol. 17: 611–616.

Lan, Q., T. Zheng, N. Rothman, Y. Zhang, S. S. Wang et al., 2006 Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107: 4101–4108.

Langeth, B., C. Trapnell, M. Pop, and S. L. Salzberg, 2009 Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10: R25.

Lansigan, F. D., M. Stearns, and F. Foss, 2010 Role of denileukin difitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res 2: 53–59.

Latini, F. R., J. P. Hemerly, B. C. Freitas, G. Oler, G. J. Higgins et al., 2011 ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence. BMC Cancer 11: 11.

Lenz, G., G. Wright, S. S. Dave, W. Xiao, J. Powell et al., 2008 Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359: 2313–2323.

Li, D., K. Achilles-Poon, S. F. Yu, R. Dere, M. Go et al., 2013 CD22-monomethyl auristatin e antibody-drug conjugate, is a potential treatment for non-Hodgkins lymphoma. Mol Cancer Ther. 12: 1255–1265.

Li, Q., J. B. Brown, H. Huang, and P. J. Bickel, 2011 Measuring reproducibility of high-throughput experiments. Ann. Appl. Stat. 5: 1752–1779.

Liang, H., X. Ding, C. Zhou, Y. Zhang, M. Xu et al., 2012 Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol. Sci. 33: 1057–1062.

Liao, J., S. E. Humphrey, S. Poston, and E. J. Taparowsky, 2011a Batf promotes growth arrest and terminal differentiation of mouse myeloid leukemia cells. Mol. Cancer Res. 9: 350–363.

Liao, W., F. Y. Goh, R. J. Betts, D. M. Kemeny, J. Tam et al., 2011b A novel anti-apoptotic role for apolipoprotein L2 in IFN-gamma-induced cytotoxicity in human bronchial epithelial cells. J. Cell. Physiol. 226: 397–406.

Lin, Q., R. Lai, L. R. Chiriac, C. Li, V. A. Thomazy et al., 2005 Constitutive activation of Jak3/STAT3 in colon carcinoma tumors and cell lines: inhibition of Jak3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167: 969–980.

Logan, M. R., K. L. Jordan-Williams, S. Poston, J. Liao, and E. J. Taparowsky, 2012 Overexpression of Batf induces an apoptotic defect and an associated lymphoproliferative disorder in mice. Cell Death Dis. 3: e310.

Lu, P. P., Z. Y. Meng, M. X. Zhou, M. W. Wang, and G. F. Dou, 2006 Immunotherapy of non-Hodgkin’s lymphomas (NHL) by anti-CD22 antibody. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14: 1258–1261 (review in Chinese).

Lu, Z., G. Jiang, P. Blume-Jensen, and T. Hunter, 2001 Epidermal growth factor-induced tumor cell invasion and metastasis initiated by phosphorylation and downregulation of focal adhesion kinase. Mol. Cell. Biol. 21: 4016–4031.

Maltepe, E., B. Keith, A. M. Arsham, J. R. Bronson, and M. C. Simon, 2000 The role of ARNT2 in tumor angiogenesis and the neural reprogramming of ARNT2 gene expression. J. Biol. Chem. 275: 30359–30366.

Morin, R., M. Bainbridge, A. Fejes, M. Hirst, M. Krzywinski et al., 2008 Profiling the Hela S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 45: 81–94.

Mototyama, M., S. Yamazaki, A. Eto-Kimura, K. Kakeshige, and T. Muta, 2005 Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J. Biol. Chem. 280: 7444–7451.

Nakata, B., S. Fukunaga, E. Noda, R. Amano, N. Yamada et al., 2008 Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology 74: 69–75.

Olsson, A., M. Norberg, A. Okvist, K. Derkow, A. Choudhury et al., 2007 Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukemia. Br. J. Cancer 97: 769–777.

Ouyang, Z., Q. Zhou, and W. H. Wong, 2009 ChiP-Seq of transcription factors predicts absolute and differential gene expression in embryonic stem cells. Proc. Natl. Acad. Sci. USA 106: 21521–21526.

Pan, M. R., M. F. Hou, H. C. Chang, and W. C. Hung, 2008 Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J. Biol. Chem. 283: 11155–11163.

Park, S., J. Lee, Y. H. Ko, A. Han, H. J. Jun et al., 2007 The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110: 972–978.

R Development Core Team, 2008 R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

Rosenwald, A., G. Wright, W. C. Chan, J. M. Connors, E. Campo et al., 2002 The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346: 1937–1947.

Rothman, N., C. F. Skibola, S. S. Wang, G. Morgan, Q. Lan et al., 2006 Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 7: 27–38.

Schimanski, C. C., R. Bahre, I. Gockel, T. Junginger, N. Simiantonaki et al., 2006 Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol. Rep. 16: 109–113.

Shao, R. H., X. Tian, G. Gorgun, A. G. Urbano, and F. M. Foss, 2002 Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2beta gene. Leuk. Res. 26: 1077–1083.

Shuai, K., G. R. Stark, I. M. Kerr, and J. E. Darnell, Jr., 1993 A single phosphotyrosine residue of Stat1 required for gene activation by interferon-gamma. Science 261: 1744–1746.

Siou, L. L., J. K. Chan, and Y. L. Kwong, 2002 Natural killer cell malignancies: clinicopathologic and molecular features. Histol. Histopathol. 17: 539–554.

Suzuki, K., H. Nakajima, Y. Saito, T. Saito, W. J. Leonard et al., 2000 Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int. Immunol. 12: 123–132.

Sweetenham, J. W., 2005 Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology (Am Soc Hematol Educ Program) 252–259.

The ENCODE Project Consortium, R. M. Myers, J. Stamatoyannopoulos, M. Snyder, I. Dunham et al., 2011 A user’s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9: e1001046.

Tirado, C. A., W. Chen, R. Garcia, K. A. Kohlman, and N. Rao, 2012 Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large b-cell lymphoma: a review of the literature. J Hematol Oncol 5: 54.

Turkson, J., 2004 STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8: 409–422.

Warnes, G. R., B. Bolker, L. Bonebakker, R. Gentleman, W. Huber et al., 2011 gplots: Various R programming tools for plotting data. Available at: http://cran.r-project.org/web/packages/gplots/index.html. Accessed October 28, 2013.

Wen, Z., Z. Zhong, and J. E. Darnell, Jr., 1995 Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241–250.

Wright, G., B. Tan, A. Rosenwald, E. H. Hurt, A. Wiestner et al., 2003 A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 100: 9991–9996.
Wu, Z. L., Y. Q. Song, Y. F. Shi, and J. Zhu, 2011 High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 4: 31.

Yan, J., M. Enge, T. Whittington, K. Dave, J. Liu et al., 2013 Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 154: 801–813.

Yang, S. Y., A. Miah, A. Pabari, and M. Winslet, 2011 Growth factors and their receptors in cancer metastases. Front. Biosci. 16: 531–538.

Yu, G. H., K. T. Montone, D. Frias-Hidvegi, R. S. Cajulis, B. A. Brody et al., 1996 Cytomorphology of primary CNS lymphoma: review of 23 cases and evidence for the role of EBV. Diagn. Cytopathol. 14: 114–120.

Zhang, X., J. Blenis, H. C. Li, C. Schindler, and S. Chen-Kiang, 1995 Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 267: 1990–1994.

Zhong, Z., Z. Wen, and J. E. Darnell, Jr., 1994 Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95–98.

Zhu, B. M., K. Kang, J. H. Yu, W. Chen, H. E. Smith et al., 2012 Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes. Nucleic Acids Res. 40: 4461–4472.

Communicating editor: T. R. Hughes